^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Purinergic receptor P1 agonist

    Related drugs:
    1m
    Cladribine Venetoclax in Monocytic AML (clinicaltrials.gov)
    P2, N=20, Recruiting, University of Colorado, Denver | N=40 --> 20
    Enrollment change
    |
    Venclexta (venetoclax)
    3ms
    ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis (clinicaltrials.gov)
    P2/3, N=204, Active, not recruiting, Queen Mary University of London | Recruiting --> Active, not recruiting
    Enrollment closed • HEOR
    3ms
    DELIVER-MS: Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS (clinicaltrials.gov)
    P4, N=800, Active, not recruiting, The Cleveland Clinic | Trial completion date: Sep 2030 --> Jul 2027
    Trial completion date
    |
    Rituxan (rituximab) • Briumvi (ublituximab-xiiy) • fingolimod • Lemtrada (alemtuzumab) • Ocrevus (ocrelizumab) • Tysabri (natalizumab)
    3ms
    Hairy Cell Leukemia Diagnosed by Flow Cytometry Despite Absence of Hairy Cells in Peripheral Blood: A Case Report. (PubMed, Cureus)
    The patient was treated with cladribine and rituximab and achieved hematological recovery. This case highlights the usefulness of FCM for the diagnosis of HCL in the presence of splenomegaly, pancytopenia, and myelofibrosis, even though hairy cells may be absent in peripheral blood.
    Journal
    |
    BRAF (B-raf proto-oncogene) • CD20 (Membrane Spanning 4-Domains A1) • IL2RA (Interleukin 2 receptor, alpha) • ITGAX (Integrin Subunit Alpha X) • ISG20 (Interferon Stimulated Exonuclease Gene 20)
    |
    BRAF V600E • BRAF V600 • CD20 positive
    |
    Rituxan (rituximab) • cladribine
    4ms
    Intercurrent presentation of hairy cell leukemia and diffuse large B-cell lymphoma with hemophagocytic lymphohistiocytosis: a case report. (PubMed, Leuk Res Rep)
    Hairy cell leukemia (HCL) is a rare, indolent B-cell lymphoma that is highly responsive to the purine analog cladribine...Further research is needed to better understand the pathophysiological links between HCL, large cell transformation, and HLH. Additionally, registry or other cross-sectional studies with larger numbers of HCL patients could clarify the exact frequency of these rare but fatal complications.
    Journal
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E
    |
    cladribine
    5ms
    CD103-Negative Hairy Cell Leukemia: A Case Report From University Teaching Hospital, Zambia. (PubMed, Case Rep Med)
    For a disease that is more prevalent in Caucasians and less common in African populations, we report an unusual case of CD103-negative classical HCL in a 43-year-old African male, who presented with refractory anemia, thrombocytopenia, and splenomegaly. In patients with refractory anemia, it is crucial to consider investigating HCL, as this may influence therapeutic decisions and, consequently, overall patient outcomes.
    Journal
    |
    ITGAE (Integrin Subunit Alpha E)
    |
    cladribine
    5ms
    A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
    P1/2, N=58, Not yet recruiting, M.D. Anderson Cancer Center
    New P1/2 trial
    |
    cytarabine
    5ms
    Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS) (clinicaltrials.gov)
    P3, N=100, Active, not recruiting, Haukeland University Hospital | Recruiting --> Active, not recruiting | Trial completion date: Mar 2026 --> Mar 2028 | Trial primary completion date: Mar 2024 --> Nov 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    cyclophosphamide • Lemtrada (alemtuzumab) • Ocrevus (ocrelizumab)
    6ms
    CLOCK-MS: Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis (clinicaltrials.gov)
    P4, N=47, Completed, Washington University School of Medicine | Active, not recruiting --> Completed
    Trial completion
    6ms
    Venetoclax used alone, or in combination with cladribine, changes the expression of apoptosis-regulating genes in chronic lymphocytic leukemia cells in vitro. (PubMed, Adv Clin Exp Med)
    Venetoclax and 2-CdA may exert their pro-apoptotic effects on CLL cells in vitro, at least in part, by stimulating the expression of several apoptosis-related genes. The antileukemic activity of VEN is further enhanced when combined with 2-CdA.
    Preclinical • Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • FADD (Fas associated via death domain) • SMAD3 (SMAD Family Member 3)
    |
    Venclexta (venetoclax) • cladribine
    7ms
    A Rare Case of Dual Clonal B-Cell Hairy Cell Leukemia: Diagnostic Challenges. (PubMed, Clin Lab)
    HCL is a rare B-cell malignancy causing pancytopenia and organ involvement. The identification of dual clonal B-cell populations is crucial for accurate diagnosis. Early diagnosis and cladribine chemotherapy are effective. Immunohistochemical and genetic testing are key for diagnosis and treatment planning.
    Journal
    |
    BRAF (B-raf proto-oncogene) • CD20 (Membrane Spanning 4-Domains A1) • CD5 (CD5 Molecule) • MME (Membrane Metalloendopeptidase) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    BRAF V600E • BRAF V600 • CD20 positive
    |
    cladribine